Karyopharm Therapeutics Inc.
KPTI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 96 institutions reported holding it in 13F filings for Q2 2026, worth $206.8M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Karyopharm Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 50 | 52 | +2 |
| Shares | 4.41M | 2.98M | −1.44M (−32.6%) |
| Value | $19.0M | $19.5M | +$444.0K (+2.3%) |
New holders (7)
Institutions that held Karyopharm Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 35,339 | $231.1K | 0.00% |
| ADAR1 Capital Management, LLC | 25,000 | $163.5K | 0.02% |
| Belvedere Trading LLC | 14,563 | $95.2K | 0.01% |
| Quent Capital, LLC | 231 | $1.51K | 0.00% |
| Rise Advisors, LLC | 131 | $857 | 0.00% |
| Advisory Services Network, LLC | 12 | $78 | 0.00% |
| Pittenger & Anderson Inc | 3 | $20 | 0.00% |
Sold out (5)
Institutions that held Karyopharm Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Eversept Partners, LP | 257,154 | $1.11M |
| Citadel Advisors LLC | 206,781 | $891.2K |
| Palo Alto Investors LP | 187,911 | $809.9K |
| Millennium Management LLC | 31,847 | $137.3K |
| Raymond James Financial Inc | 90 | $388 |